CAMIDANLUMAB

UNII:	UP9K666A04
Formula:
Preferred Substance Name:	CAMIDANLUMAB

921618-45-3
CAMIDANLUMAB [INN]
CAMIDANLUMAB [USAN]
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 2 RECEPTOR .ALPHA. CHAIN)(HUMAN HUMAX-TAC HEAVY CHAIN), DISULFIDE WITH HUMAN HUMAX-TAC LIGHT CHAIN, DIMER
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS INTERLEUKIN-2 RECEPTOR SUBUNIT ALPHA (TAC ANTIGEN, P55, CD25 ANTIGEN)), HOMO SAPIENS MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-445) (HOMO SAPIENS VH (IGHV1-69*02 (95%) (IGHD)-IGHJ4*01 (93%)) (8.8.8) (1-115) -HOMO SAPIENS IGHG1*03 (116-445)), (218-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-214') (HOMO SAPIENS V-KAPPA (IGKV3-20*01 (99%) IGKJ4*01)(6.3.9) (1'-107') -HOMO SAPIENS IGKC*01 (108'-214'))DIMER (224-224'':227-227'')-BISDISULFIDE

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

CAMIDANLUMAB

Synonyms and Mappings

Resources